DGAP-Adhoc: FDA approves once-monthly Abilify Maintena (aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia

H. Lundbeck A/S 01.03.2013 00:01 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- -- Approval provides patients with schizophrenia the ability to access the efficacy and safety profile of oral aripiprazole in a once-monthly formulation -- Relapse prevention is an important consideration in the tr
Source: Medical News (via PRIMEZONE) - Category: Pharmaceuticals Source Type: news